Weekly review in ophthalmology: 24-30 September

An end-of-week review of what happened in ophthalmology from 24 to 30 September 2022.

Check out what Ophthalmology Times Europe shared this week:

Ophthalmology news

Genetic testing for keratoconus facilitates earlier recognition of condition

Great strides have been made in recognising and treating keratoconus. Recent imaging technologies, such as optical coherence tomography, have identified thinning of corneal tissue over the cone, and wave-front aberrometry shows higher-order aberrations that may facilitate the diagnosis.

Yet the pathway to diagnosing the condition is not always free of roadblocks, according to Dr Sumit Garg, professor of cataract, corneal and refractive surgery at the Gavin Herbert Eye Institute, University of California, Irvine, California, United States. Dr Garg said that keratoconus has two components: genetic and environmental. The latter, he said, includes allergies and eye rubbing (during waking and sleeping hours), which is a huge driver of keratoconus progression. If eye rubbing persists, progression can occur despite cross-linking treatment.

Dr Garg also pointed out that the diagnosis can depend on where a patient lives and their genetic make-up. “The keratoconus prevalence is individualised and [keratoconus] can be prevalent in up to 5% of particular populations as shown in a recent study,” he said. With the rapid advancements in this field, the next step is determining the role of genetic testing in this patient population.

Continue reading

Corneal ectasia part 3: OCT epithelial thickness measurements allow monitoring of corneal changes

This is the third in a series of articles that summarises an afternoon of presentations, plus a debate, on the topic of corneal ectasia that was held as part of the recent 29th Cologne Adventsymposium, an annual meeting organised by Laserforum e.V., in Cologne, Germany. Chaired by Drs Omid Kermani and Georg Gerten, the presentations each considered the condition from a different perspective and are available online.

Read more

Poor post-pandemic follow-up care in glaucoma patients prompts concern

A high percentage of patients diagnosed with glaucoma missed follow-up evaluations 15 months after glaucoma appointments had been cancelled during the COVID-19 pandemic in the United States, according to investigators. After examinations resumed, the researchers found that many of the established patients who did not return for follow-up evaluations tended to be elderly.

A retrospective chart review study was conducted by Ms Catherine Wang, of the University of Illinois College of Medicine at Chicago, Illinois, United States—along with colleagues from the Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences at the University of Illinois at Chicago. They examined the percentages of patients who returned for evaluations at 6 months, 12 months and later, following cancellation of their examinations.

The study also sought to determine the demographic and socioeconomic factors related to the patients who did not return for evaluation after 15 months, as well as the effects that the lack of follow-up care had on patients with glaucoma.

Explore here

Mont Blanc: Final visit completed in Phase 3 trial of NCX 470 for the treatment of glaucoma

Nicox SA announced that the last patients completed their final (3-month) visit in the Mont Blanc Phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

A total of 691 patients were enrolled in the trial. NCX 470, Nicox’s lead clinical product candidate, is a novel, potentially best-in-class, nitric oxide (NO)-donating prostaglandin analogue eye drop.

“We are pleased to have reached this milestone in the Mont Blanc Phase 3 clinical trial, and I would particularly like to thank our clinical sites and the Nicox development team for their incredible efforts in continuing to drive this trial to completion in the face of the COVID-19 pandemic situation.” Doug Hubatsch, EVP, Chief Scientific Officer of Nicox, said in a news release. “NCX 470 has the potential to be a best-in-class glaucoma treatment, and we look forward to sharing the top line results in early November.”

Learn more

ESCRS 2022

Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in

Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."

Watch the interview

Investigating better indications and outcomes in laser refractive surgery

Prof. Martin Dirisamer speaks with Editor Caroline Richards about his ESCRS instructional course, "Mastering laser refractive surgery: Indications and outcomes."

Watch the video